Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
$2.00
+0.3%
$1.64
$1.17
$21.92
$12.11M0.041.22 million shs300,852 shs
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$1.58
-0.6%
$1.48
$0.99
$5.77
$99.68M1.59849,370 shs1.16 million shs
Provention Bio, Inc. stock logo
PRVB
Provention Bio
$24.98
$24.58
$3.18
$25.00
$2.37B2.472.28 million shs218,200 shs
Urogen Pharma stock logo
URGN
Urogen Pharma
$14.64
+6.0%
$9.82
$3.42
$18.15
$675.05M1.021.09 million shs1.46 million shs
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$4.99
-0.6%
$4.48
$3.81
$6.37
$294.06M0.68603,759 shs507,094 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-0.50%+3.63%+2.04%+21.95%-88.43%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
+8.16%+15.22%-3.05%+27.20%-62.81%
Provention Bio, Inc. stock logo
PRVB
Provention Bio
0.00%0.00%0.00%0.00%0.00%
Urogen Pharma stock logo
URGN
Urogen Pharma
+0.73%+6.56%+96.72%+47.07%-17.11%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
+3.29%+2.66%+9.37%+23.04%-5.64%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
4.4735 of 5 stars
3.34.00.04.53.01.70.6
MacroGenics, Inc. stock logo
MGNX
MacroGenics
4.1396 of 5 stars
3.23.00.04.41.32.50.6
Provention Bio, Inc. stock logo
PRVB
Provention Bio
N/AN/AN/AN/AN/AN/AN/AN/A
Urogen Pharma stock logo
URGN
Urogen Pharma
4.5504 of 5 stars
4.52.00.04.52.52.50.0
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
4.3861 of 5 stars
3.82.00.04.20.63.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
2.67
Moderate Buy$42.601,943.17% Upside
MacroGenics, Inc. stock logo
MGNX
MacroGenics
2.40
Hold$5.71256.03% Upside
Provention Bio, Inc. stock logo
PRVB
Provention Bio
0.00
N/AN/AN/A
Urogen Pharma stock logo
URGN
Urogen Pharma
3.00
Buy$32.86128.02% Upside
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
3.50
Strong Buy$16.50228.36% Upside

Current Analyst Ratings Breakdown

Latest VNDA, URGN, PRVB, MGNX, and BTAI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
7/7/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
6/16/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$50.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetNeutral ➝ Neutral$16.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Buy$31.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$23.00 ➝ $47.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $30.00
6/12/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
6/3/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$36.00 ➝ $10.00
5/20/2025
MacroGenics, Inc. stock logo
MGNX
MacroGenics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$5.00 ➝ $3.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
$1.85M6.82N/AN/A($30.01) per share-0.07
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$149.96M0.68N/AN/A$1.85 per share0.87
Provention Bio, Inc. stock logo
PRVB
Provention Bio
$12.90M183.54N/AN/A$1.40 per share17.84
Urogen Pharma stock logo
URGN
Urogen Pharma
$90.40M7.35N/AN/A($0.21) per share-68.62
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$198.77M1.49N/AN/A$9.24 per share0.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-$59.60M-$13.55N/AN/AN/A-2,163.18%N/A-83.80%8/5/2025 (Estimated)
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$66.97M-$0.89N/AN/AN/A-36.23%-59.84%-23.45%8/5/2025 (Estimated)
Provention Bio, Inc. stock logo
PRVB
Provention Bio
-$113.57M-$1.53N/AN/AN/A-880.69%-103.36%-69.08%N/A
Urogen Pharma stock logo
URGN
Urogen Pharma
-$126.87M-$3.18N/AN/AN/A-150.68%-97,487.15%-49.57%8/12/2025 (Estimated)
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$18.90M-$0.75N/AN/AN/A-21.98%-8.30%-6.85%7/30/2025 (Estimated)

Latest VNDA, URGN, PRVB, MGNX, and BTAI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-$2.30N/AN/AN/A$0.21 millionN/A
8/5/2025Q2 2025
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$0.59N/AN/AN/A$28.06 millionN/A
7/30/2025Q2 2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.34N/AN/AN/A$54.77 millionN/A
5/13/2025Q1 2025
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$0.61-$0.65-$0.04-$0.65$9.59 million$13.19 million
5/12/2025Q1 2025
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-$2.72-$1.50+$1.22-$1.50$0.35 million$0.17 million
5/12/2025Q1 2025
Urogen Pharma stock logo
URGN
Urogen Pharma
-$0.83-$0.92-$0.09-$0.92$22.71 million$20.25 million
5/7/2025Q1 2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.55-$0.50+$0.05-$0.50$45.13 million$50.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
N/AN/AN/AN/AN/A
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/AN/AN/AN/AN/A
Provention Bio, Inc. stock logo
PRVB
Provention Bio
N/AN/AN/AN/AN/A
Urogen Pharma stock logo
URGN
Urogen Pharma
N/AN/AN/AN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
N/A
1.48
1.45
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/A
3.28
3.11
Provention Bio, Inc. stock logo
PRVB
Provention Bio
0.19
1.93
1.92
Urogen Pharma stock logo
URGN
Urogen Pharma
N/A
5.65
5.47
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/A
3.93
3.91

Institutional Ownership

CompanyInstitutional Ownership
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
30.68%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
96.89%
Provention Bio, Inc. stock logo
PRVB
Provention Bio
37.39%
Urogen Pharma stock logo
URGN
Urogen Pharma
91.29%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
88.14%

Insider Ownership

CompanyInsider Ownership
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
21.20%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
13.00%
Provention Bio, Inc. stock logo
PRVB
Provention Bio
13.10%
Urogen Pharma stock logo
URGN
Urogen Pharma
5.10%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
10.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
906.06 million4.77 millionOptionable
MacroGenics, Inc. stock logo
MGNX
MacroGenics
43063.09 million54.89 millionOptionable
Provention Bio, Inc. stock logo
PRVB
Provention Bio
8294.78 million82.37 millionNot Optionable
Urogen Pharma stock logo
URGN
Urogen Pharma
20046.11 million43.76 millionOptionable
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
29058.93 million53.04 millionOptionable

Recent News About These Companies

VNDA - Vanda Pharmaceuticals Inc Executives - Morningstar
VNDA - Vanda Pharmaceuticals Inc Chart - Morningstar
Brokers Issue Forecasts for VNDA FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioXcel Therapeutics stock logo

BioXcel Therapeutics NASDAQ:BTAI

$2.00 +0.01 (+0.25%)
Closing price 04:00 PM Eastern
Extended Trading
$2.04 +0.04 (+1.75%)
As of 05:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

MacroGenics stock logo

MacroGenics NASDAQ:MGNX

$1.58 -0.01 (-0.63%)
Closing price 04:00 PM Eastern
Extended Trading
$1.61 +0.03 (+2.15%)
As of 05:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Provention Bio stock logo

Provention Bio NASDAQ:PRVB

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Urogen Pharma stock logo

Urogen Pharma NASDAQ:URGN

$14.64 +0.83 (+6.01%)
Closing price 04:00 PM Eastern
Extended Trading
$14.60 -0.04 (-0.31%)
As of 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Vanda Pharmaceuticals stock logo

Vanda Pharmaceuticals NASDAQ:VNDA

$4.99 -0.03 (-0.60%)
Closing price 04:00 PM Eastern
Extended Trading
$4.93 -0.06 (-1.20%)
As of 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.